← Back to headlines
BioNTech Adjusts Forecast, New CEO to Focus on Cancer Drugs Amid Vaccine Revenue Decline
BioNTech has adjusted its financial forecast as new CEO Guido Oelkers takes the helm, with the company now prioritizing the success of two cancer medications to offset declining revenues from its vaccine business.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
